Skip to main content
Premium Trial:

Request an Annual Quote

AutoGenomics and Targeted Molecular Dx to Co-Develop Cancer Biomarker Test on Microarray Platform

NEW YORK, July 28 (GenomeWeb News) - AutoGenomics of Carlsbad, Calif., and Targeted Molecular Diagnostics of Westmont, Ill., will co-develop cancer biomarkers for pharmacogenomic tests on a microarray platform, the companies said yesterday.


Under the three-year partnership, Targeted Molecular will develop BioFilmChip microarray content, based on its knowledge of signaling pathways, while AutoGenomics will develop the tests on its Infiniti platform.


The first test will be a gene expression assay for tumor response and resistance to compounds targeting the HER1 and HER2 pathways. Future assays will cover breast cancer response to therapies, apoptotic response, and resistance to chemotherapy.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.